Skip to main content

Adverum Biotechnologies Value Stock - Dividend - Research Selection

Adverum Biotechnologies

ISIN: US00773U1088, WKN: A2AJW8

Market price date: 25.09.2020
Market price: 10,81 USD




Adverum Biotechnologies Fundamental data and company key figures of the share

Annual reports in USD
Key figures 11-09-2020
Cash flow
Net operating cash flow -49.170.000
Capital Expenditures -19.247.000
Free cash flow -68.417.000
Balance sheet
Total Equity 174.957.000
Liabilities & Shareholders equity 222.727.000
Income statement
Net income -64.486.000
Eps (diluted) -1,010
Diluted shares outstanding 63.847.500
Net sales/revenue 250.000

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -13,63
   
P/FC -9,80
Balance sheet
ROI-28,95
ROE78,55
Income statement
P/E-10,70
Div. Yield0,00%
P/B3,83
P/S2.760,77


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolADVM
Market Capitalization670.398.720,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.adverum.com


Description of the company

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.adverum.com